BRIEF-Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
ReutersFeb 4, 2025 1:41 PM
Feb 4 (Reuters) - Mineralys Therapeutics Inc MLYS.O:
MINERALYS THERAPEUTICS COMPLETES ENROLLMENT IN EXPLORE-CKD PHASE 2 TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION IN SUBJECTS WITH STAGE 2 TO 3B CKD AND ALBUMINURIA
MINERALYS THERAPEUTICS INC - TO SHARE TOPLINE DATA FROM EXPLORE-CKD TRIAL IN Q2 2025
Source text: ID:nGNX4dfjTL
Further company coverage: MLYS.O
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
BHP’s 2025 Playbook: Turning Profit Dips into Strategic Wins
TradingKey - On August 18, 2025, BHP Group announced its full-year results for the 2025 fiscal year. Despite an 8% year-on-year revenue decline to $51.3 billion and a 26% significant drop in underlying attributable profit, which reflects core business performance, to $10.2 billionTradingKey
13 hours ago
U.S. Stock Market Risk Assessment: Learning from History, Mid-Term Outlook Remains Secure
We argue that the Federal Reserve’s monetary policy is the most critical factor influencing the stock market.TradingKey
Mon, Aug 18
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed ChairTradingKey
Mon, Aug 18
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
Mon, Aug 18
Amazon Q2 FY2025 Earnings Review: Robust Cloud and AI Growth Coupled with Retail Tariff Challenges
TradingKey - Amazon.com, Inc. (NASDAQ: AMZN) released its Q2 FY2025 earnings on July 31, 2025, after market close, delivering results that surpassed expectations, driven by robust growth in AWS, advertising, and retail segments.TradingKey
Fri, Aug 1
